Investment Thesis

With 7% top-line growth and 8% bottom-line growth across the majority of its divisions, Abbott Labs reported a solid first-quarter performance. Due to the possibility of sustained high healthcare utilization in 2024, the company's growth is anticipated to continue in 2025. The Libre franchise, structural heart, and heart failure were the main drivers of the 13% annual growth in medical devices. Weak sales of COVID tests caused Diagnostics to drop 5%. Tariffs are predicted to have an annual impact of about $300 million, with an additional $500 million in 2026. Abbott anticipates further increases in its gross margin in 2027 as a result of optimizing its manufacturing footprint to reduce tariff exposure. The company's Volt pulsed field ablation device was approved by European regulators, which may help it take market share away from rivals. Abbott has used its mapping technology to defend its electrophysiology business, even though it was late to introduce its own PFA ablation catheters, falling behind Boston Scientific and Medtronic. Whether practitioners will leave Abbott or move to Volt is still up in the air.

Competitive Overview

Drugs: Regarding the drug industry, Abbott comes head to head with Pfizer, Novartis, and Johnson & Johnson. Much like Abbott, these rivals are focusing on the same therapeutic fields, like cardiovascular health and diabetes management, and are taking away parts of the Abbott market due to their advanced research potential and wide range of medicines.

Medical Equipment: The medical devices division pits Abbott against Medtronic, Boston Scientific, and Stryker. These competitors produce devices that are relevant to cardiovascular devices, neuromodulation, and diabetes care, for example, Abbott's FreeStyle Libre, which is a glucose monitoring system. Competition is fueled by ongoing international patent disputes, the latest of which was with Medtronic regarding the cardiovascular devices technology, which led to legal and innovative pressures.

Diagnostics: In the diagnostic field, Abbott is the one that dominates the market by a large margin, especially after its breakthrough COVID-19 testing kits. But Roche, Siemens Healthineers, and Thermo Fisher Scientific being fierce rivals make things a little tough for it, as all of them supply analog diagnostic tests and devices. A rivalry of this magnitude was seen across the pandemic period, as demand for effective and trusted testing processes increased, they had no choice but to keep coming up with new ideas.

Story Continues

Food: The section related to food has Abbott contesting with Nestle, Danone, and Reckitt Benckiser. Such rivals are selling equivalent products like baby formula (e.g., Abbott's Similac vs. Nestle's NAN) and adult nutrition, catching consumer trust and shelf space in a highly brand-driven market.

Investment Upsides

The market is dominated by three or four competitors, including those in the following areas: immunoassays, coronary stents, venous closure, continuous glucose monitors, cardiac rhythm management devices, surgical heart valves, and nutrition. Abbott benefits from intangible assets that generate economic profits in these markets. One of Abbott's most lucrative divisions is the nutritional division, which holds a dominant position in a highly consolidated market valued at an estimated $35 billion globally. The company has created proprietary formulas of specialty infant formulas for infants with allergies and metabolic issues, as well as intangible assets like brand trust with pediatricians and new parents.

Product Mix

Due to the rise in middle-class families and the resulting demand for adult and pediatric nutrition products, ambient markets, including emerging markets, present more promising long-term growth prospects. Abbott is able to enter new markets thanks to its powerful Similac and Ensure brands, which give it an edge when launching new formulations and line extensions. Known as branded generics, Abbott's well-established pharmaceutical product line primarily sells to pharmacies and doctors directly, functioning more like a consumer business than traditional branded medications. Abbott's primary advantages in this market are its reputation and brand recognition, which could shift in the long run as more emerging markets adopt the developed-nation tender system.

Financial impact post St. Jude's acquisition:

The 2017 acquisition of St. Jude Medical by Abbott for $25 billion was a high game changer in the cardiovascular segment. As a leading company in vascular care, Abbott, which combines the St. Jude's strength in the areas of heart failure, arrhythmia, and structural heart devices, has increased its market share effectively. The company revealed that it held the No. 1 or No. 2 positions in the cardiovascular segment, which comprises a $30 billion market, resulting from the accomplishment of a considerable increase in market presence that is inherent to the above-mentioned situation.

Moreover, a revenue boost was also experienced. In 2016, the cardiovascular sales of Abbott were $2.9 billion. After including St. Jude's $5.5 billion, the total sales for the year 2017 reached the fantastic figure of $10.7 billion. The organic growth was down by 2.9%, but this was due to the integration, which was, of course, a temporary effect. To continue the growth story, in 2018, the organic growth was at 10.1%, in 2019 it was at 7.3%. Thus, it can be said that the acquisition gave a solid push in the long run.

Although the first year of the acquisition saw the profitability get hit, recently there has been a turnaround. The medical devices segment experienced a decrease in operating margin from 38% in 2016 to 13% in 2017 mainly because of the integration expenses tagging along. Nevertheless, it was on track again in 2018 with 18% operating margin and again in 2019 with a further increase to 20% operating margin, all this due to the $500 million in annual synergies attained by 2020. In summary, the acquisition facilitated the growth of Abbott by enhancing its market position, increasing the revenue, and after the initial challenges, the profitability in the cardiovascular segment improved.

Integration of St. Jude's Technologies

Abbott gains a great deal from legacy St. Jude's remarkable proficiency in heart failure, structural heart, and cardiac rhythm management. Specialized engineering knowledge, proficiency in navigating the regulatory pathway, and solid sales representative relationships with practitioners are examples of intangible assets in this segment. After being implanted inside the body, high-margin devices like pacemakers, cardiac resynchronization devices, spinal cord stimulators, and implantable cardioverter defibrillators benefit from high switching costs. The diagnostics segment exhibits switching costs, which are common in the life sciences market, and deviates slightly from the other divisions. Abbott uses intellectual property to protect some degree of product differentiation and to keep rivals out of the device and diagnostic markets. In the field of medical technology, patents are not infallible, though, because rivals may develop a different approach to a comparable solution. Although Abbott's businesses show signs of moatiness, there is less confidence in the company's long-term ability to foster and revitalize innovation. The business is more likely to follow Boston Scientific and Medtronic to market than to forge its own route.

Intrinsic ValuationFrom Acquisition to Advantage: Abbott's Growth in Heart Care

ABT's shares are modestly overvalued. Despite the COVID-19 crisis, Abbott's balance sheet has remained a solid pillar of strength. Leverage was increased by the acquisitions of Alere and St. Jude Medical, and the company's debt to EBITDA ratio has remained at about 1.5 times, suggesting that it can produce $6 billion to $7 billion in free cash flow annually. Abbott has been able to support large dividend increases and make more tuck-in acquisitions thanks to the Covid-19 windfall. Over the next few years, the company's estimated interest coverage of EBITDA/interest will increase to 20 times.

Revenue from non-COVID diagnostics is anticipated to remain stable in 2025, with Abbott largely regaining market share in infant formula. The established pharmaceuticals business will stabilize with mid-single-digit growth, and procedure volume will continue to be strong. There will be a moderate uptake of Abbott's recent new product launches, such as the Amplatzer Amulet for left atrial appendage closure. Throughout the explicit forecast period, the company can increase its operating margin by about 230 basis points, mostly as a result of new products and a closing operating margin gap between Abbott and its main rivals. Notable Guru HoldingsFrom Acquisition to Advantage: Abbott's Growth in Heart Care

Jeremy Grantham (Trades, Portfolio) (Trades, Portfolio) 48 Abbott Laboratories transactions (GMO Asset.png" data-href="" style=""/>From Acquisition to Advantage: Abbott's Growth in Heart Care

Ken Fisher (Trades, Portfolio) (Trades, Portfolio) 48 Abbott Laboratories transactions (Fisher Asset.png" data-href="" style=""/>From Acquisition to Advantage: Abbott's Growth in Heart Care

Jeremy Grantham (Trades, Portfolio) of GMO LLC, knowing for his long term investment philosophy had been buying shares since 2023 and ABT has awarded him with commendable returns as his average buying price stands at $53.9.

Investment Downsides

The potential commercial success of Abbott's Libre franchise, which includes expansions to new patient populations, and persistent problems with its left ventricular assist devices are among the risks the company faces. Additionally, the business is susceptible to disruptive innovation from competitors, especially in its diagnostic and medical device divisions. Abbott faced a significant formula recall in the US as a result of Cronobacter poisoning cases, despite efforts to safeguard itself against recalls. There is still a chance of product quality problems or recalls, which could harm the company's reputations and connections with healthcare providers. Abbott is under more pressure to lower prices due to tighter budgets and more competitive tenders in China. The US Food and Drug Administration and regulatory bodies abroad also keep an eye on Abbott's operations, which may cause delays in product approvals or manufacturing.

Portfolio Management

While Abbott has acquired some noteworthy companies, like Knoll and St. Jude Medical, it has also acquired less noteworthy companies, like Advanced Medical Optics and the Guidant stent division. Given that the majority of its cardiovascular portfolio was acquired through mergers and acquisitions, the company's capacity to foster innovation after acquiring assets is a cause for concern. Given Abbott's history of dividend increases and dividend payments, the level of shareholder distributions is appropriate. However, these buybacks were somewhat dilutive because the company spent $1.5 billion on repurchasing shares in 2020 and 2021, right when demand for diagnostics related to the pandemic was booming.

This article first appeared on GuruFocus.

View Comments